InvestLog
QNRX Quoin Pharmaceuticals, Ltd. logo

QNRX Quoin Pharmaceuticals, Ltd.

Healthcare
$4.77-1.65%ClosedMarket Cap: $2.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.07

P/S

0.00

EV/EBITDA

0.02

DCF Value

$2,547.49

FCF Yield

-565.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-292.3%

ROA

-108.2%

ROIC

-168.7%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-5.0M$—
Q4 null$0.00$-4.3M$—
FY null$0.00$-15.8M$—
Q3 null$0.00$-3.9M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

1 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
Stonepine Capital Management, LLC10 percent owner:
SellTue Mar 31
SEMBER MICHAEL Tdirector
SellFri Feb 06
Myers Michaeldirector, officer: Chief Executive Officer
SellFri Feb 06
Leong Natalie Ee Mundirector
SellFri Feb 06
Lawlor Sally Bridgetofficer: Chief Financial Officer
SellFri Feb 06

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

1.62

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Peers

CYCN logoCYCNKTTA logoKTTANBY logoNBYPLRZ logoPLRZPMCB logoPMCBRADX logoRADXTCRT logoTCRTVIVS logoVIVSVYNE logoVYNEXTLB logoXTLB